[HTML][HTML] Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings
This subgroup analysis of COMPACT trial data suggests that patients with hereditary
angioedema using intravenous human C1-inhibitor as routine prophylaxis can derive a
clinically meaningful benefit when switched to prophylaxis with subcutaneous human C1-
inhibitor, observable as a further reduction in hereditary angioedema attacks.
angioedema using intravenous human C1-inhibitor as routine prophylaxis can derive a
clinically meaningful benefit when switched to prophylaxis with subcutaneous human C1-
inhibitor, observable as a further reduction in hereditary angioedema attacks.
以上显示的是最相近的搜索结果。 查看全部搜索结果